Cannabinol Derivatives
J ournal of Medicinal Chemistry, 1997, Vol. 40, No. 20 3233
(9) Munro, S.; Thomas, K. L.; Abu-Shaar, M. Molecular character-
ization of a peripheral receptor for cannabinoids. Nature 1993,
365, 61-65.
were assayed for adenylylcyclase activity. Transfection ef-
ficiency, determined by transfection with the cDNA for â-ga-
lactosidase, was 40-80%.
(10) Razdan, R. K. Structure-activity relationships in cannabinoids.
Pharmacol. Rev. 1986, 38, 75-149.
Ad en ylylcycla se Assa y. The assay were performed as
described.11,12,27 Cells cultured in 24-well plates were incu-
bated for 3 h with 0.25 mL/well fresh growth medium contain-
ing 5 µCi/mL [3H]adenine. This medium was replaced with
Dulbecco’s modified Eagle’s medium containing 20 mM Hepes
(pH 7.4), 1 mg/mL fatty acid-free bovine serum albumin, 0.5
mM 1-methyl-3-isobutylxanthine, and 0.5 mM RO-20-1724.
Cannabinoids and forskolin (1 µM) were added, and the cells
were incubated at 37 °C for 10 min. The reaction was
terminated with 1 mL of 2.5% perchloric acid containing 0.1
mM unlabeled cAMP. Aliquots of 0.9 mL were neutralized
with 100 µL of 3.8 M KOH and 0.16 M K2CO3 and applied to
a two-step column separation procedure.12,27 The [3H]cAMP
was eluted into scintillation vials and counted. Background
levels (cAMP accumulation in the absence of forskolin) were
subtracted from all values and represented less than 10% of
forskolin-stimulated cAMP accumulation.
(11) Bayewitch, M.; Avidor-Reiss, T.; Levy, R.; Barg, J .; Mechoulam,
R.; Vogel, Z. The peripheral cannabinoid receptor: adenylate
cyclase inhibition and G protein coupling. FEBS Lett. 1995, 275,
143-147.
(12) Bayewitch, M.; Rhee, M.-H.; Avidor-Reiss, T.; Breuer, A.;
Mechoulam, R.; Vogel, Z. (-)-∆9-Tetrahydrocannabinol antago-
nizes the peripheral cannabinoid receptor-mediated inhibition
of adenylylcyclase. J . Biol. Chem. 1996, 271, 9902-9905.
(13) Mechoulam, R.; Ben-Shabat, S.; Hanusˇ, L; Ligumsky, M.;
Kaminski, N. E.; Schatz, A. R.; Gopher, A.; Almog, S.; Martin,
B. R.; Compton, D. R.; Pertwee, R. G.; Griffin, G.; Bayewitch,
M.; Barg, J .; Vogel, Z. Identification of an endogenous 2-mono-
glyceride, present in canine gut, that binds to cannabinoid
receptors. Biochem. Pharmacol. 1995, 50, 83-90.
(14) Devane, W. A.; Hanusˇ, L.; Breuer, A.; Pertwee, R. G.; Stevenson,
L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.;
Mechoulam, R. Isolation and structure of a brain constituent
that binds to the cannabinoid receptor. Science 1992, 258, 1946-
1949. Hanusˇ, L.; Gopher, A.; Almog, S.; Mechoulam, R. Two new
unsaturated fatty acid ethanolamides in brain that bind to the
cannabinoid receptor. J . Med. Chem. 1993, 3032-3034.
(15) Gaoni, Y.; Mechoulam, R. Isolation, structure and partial
synthesis of an active constituent of hashish. J . Am. Chem. Soc.
1964, 86, 1646.
Sta tistica l An a lysis. Data were anlyzed using the Stu-
dent’s t-test. Inhibition curves were generated with the Sigma
Plot 4.11 program, and the EC50 values were determined using
an equation from the ALLFIT program.30
(16) Gaoni, Y.; Mechoulam, R. The isolation and structure of ∆1-THC
and other neutral cannabinoids from hashish. J . Am. Chem. Soc.
1971, 93, 217-224.
Ack n ow led gm en t. This work was supported by
NIDA grants DA 9789 and DA 8169 (to R.M.) and a
grant by the Israel Science Foundation (to Z.V. and
R.M.), the Forchheimer Center for Molecular Genetics
(to Z.V.), and the Henry and Anne Reich Research Fund
for Mental Health (to Z.V.). M.B. was supported by a
fellowship from the Israeli Ministry of Science and
Technology. Z.V. is the incumbent of the Ruth and
Leonard Shimon Chair of Cancer Research. R.M. is the
Lionel J acobson Professor Medicinal Chemistry. The
authors thank Drs. T. Bonner (NIMH, NIH, Bethesda,
MD), S. Munro (Cambridge, U.K.), and T. Pfeuffer
(Dusseldorf, Germany) for their kind donations of plas-
mids encoding CB1, CB2, and adenylylcyclase type V,
respectively.
(17) Baek, S.-H.; Srebnik, M.; Mechoulam, R. Boron trifluoride
etherate on alimina - A modified Lewis acid reagent. An
improved synthesis of cannabidiol. Tetrahedron Lett. 1985, 26,
1083-1086.
(18) Loev, B. Dibenzo[b,d]pyran compounds. U.S. Patent 3,799,946,
1974.
(19) Ben Zvi, Z.; Mechoulam, R.; Burstein, S. H. Synthesis of ∆1(6)
THC metabolites. Tetrahedron Lett. 1970, 4495-4497.
-
(20) Mechoulam, R.; Lander, N.; Breuer, A.; Zahalka, J . Synthesis
of the individual, pharmacologically distinct, enantiomers of a
tetrahydrocannabinol derivative. Tetrahedron: Asymmetry 1990,
1, 315-319.
(21) Mechoulam, R.; Ben-Zvi, Z.; Agurell, S.; Nilsson, I. M.; Nilsson,
J . L. G.; Edery, H.; Grunfeld, Y. ∆6-Tetrahydrocannabinol-7-oic
acid, a urinary ∆6-THC metabolite: isolation and synthesis.
Experientia 1973, 29, 1193-1195.
(22) Harvey, D. J .; Martin, B.; Paton, W. D. M. In vivo metabolism
of cannabinol by the mouse and rat and a comparison with the
metabolism of ∆1-tetrahydrocannabinol and cannabidiol. Biomed.
Mass Spectrom. 1977, 4, 364-369.
(23) Burstein, S. H.; Audette, C. A.; Breuer, A.; Devane, W. A.;
Colodner, S.; Doyle, S. A.; Mechoulam, R. Synthetic nonpsycho-
tropic cannabinoids with potent antiinflammatory, analgesic and
leukocyte antiadhesion activities. J . Med. Chem. 1992, 35, 3135-
3141.
(24) (a) Adams, R.; Baker, B. R. Structure of cannabinol. A second
method of synthesis of cannabinol. J . Am. Chem. Soc. 1940, 62,
2401. (b) Ghosh, R.; Todd, A. R.; Wilkinson, S. The synthesis of
cannabinol. J . Chem. Soc. 1940, 1393. (c) Adams, R.; Mackenzie,
S., J r.; Loewe, S. Tetrahydrocannabinol homologs with doubly
branched alkyl groups in the 3-position. J . Am. Chem. Soc. 1948,
70, 664. (d) For a review, see: Mechoulam, R. Cannabinoid
Chemistry. In Marijuana, Chemistry, Pharmacology, Metabolism
and Clinical Effects; Mechoulam, R., Ed.; Academic Press: New
York, 1973; pp 1-99.
(25) Matsuda, L. A.; Lolait, S. J .; Brownstein, M. J .; Young, A. C.;
Bonner, T. I. Structure of a cannabinoid receptor and functional
expression of the cloned cDNA. Nature 1990, 346, 561-564.
(26) Devane, W. A.; Breuer, A.; Sheskin, T.; J a¨rbe, T. U. C.; Eisen,
M.; Mechoulam, R. A novel probe for the cannabinoid receptor.
J . Med. Chem. 1992, 35, 2065-2069.
(27) Vogel, Z.; Barg, J .; Levy, R.; Saya, D.; Heldman, E.; Mechoulam,
R. Anandamide, a brain endogenous compound, interacts specif-
ically with cannabinoid receptors and inhibits adenylate cyclase.
J . Neurochem. 1993, 61, 352-355.
(28) Agurell, S.; Halldin, M.; Lindgren, J .-E.; Ohlsson, A.; Widman,
M.; Gillespie, H.; Hollister, L. Pharmacokinetics and metabolism
of ∆1-tetrahydrocannabinol and other cannabinoids with em-
phasis on man. Pharmacol. Rev. 1986, 38, 1, 21-43.
(29) Levitzki, A. Receptors. A Quantitative Approach; The Benjamin/
Cummings Publishing Co.: Menlo Park, CA, 1984; pp 19-36.
(30) DeLean, A.; Munson, P. J .; Rodbard, D. A User’s Guide to
ALLFIT; National Institutes of Health: Bethesda, MD; pp
97-102.
Refer en ces
(1) Pertwee, R., Ed. Cannabinoid Receptors; Harcourt Brace & Co.:
London, 1995.
(2) Howlett, A. C. Pharmacology of cannabinoid receptors. Annu.
Rev. Pharmacol. Toxicol. 1995, 35, 607-634. Piomelli, D.
Arachidonic Acid in Cell Signalling; R. G. Landes Co.: Austin,
TX, 1996.
(3) Herkenham, M. Localization of cannabinoid receptors in brain
and periphery. In Cannabinoid Receptors; Pertwee, R., Ed.;
Harcourt Brace & Co.: London, 1995; pp 145-166.
(4) Galiegue, S.; Mary, S.; Marchand, J .; Dussossoy, D.; Carriere,
D.; Carayon, P.; Bouaboula, M.; Shire, D.; Lefur, G.; Casellas,
P. Expression of central and peripheral cannabinoid receptors
in human immune tissues and leukocyte subpopulations. Eur.
J . Biochem. 1995, 232, 55-61.
(5) Mechoulam, R.; Devane, W. A.; Glaser, R. Cannabinoid geometry
and biological activity. In Marijuana/ Cannabinoids: Neurobi-
ology and Neurophysiology; Murphy, L., Bartke, A., Eds.; CRC
Press: Boca Raton, FL, 1992; pp 1-33.
(6) Martin, B. R.; Thomas, B. F.; Razdan, R. K. Structural require-
ments for cannabinoid receptor probes. In Cannabinoid Recep-
tors; Pertwee, R., Ed.; Harcourt Brace & Co.: London, 1995; pp
36-85.
(7) Melvin, L. S.; Milne, G. M.; Ross J ohnson, M.; Wilken, G. H.;
Howlett, A. C. Structure-activity relationships defining the ACD-
tricyclic cannabinoids: cannabinoid receptor binding and anal-
gesic activity. Drug Des. Discov. 1995, 13, 155-166.
(8) (a) Gareau, Y.; Dufresne, C.; Gallant, M.; Rochette, C.; Sawyer,
N.; Slipetz, D. M.; Tremblay, N.; Weech, P. K.; Metters, K. M.;
Labelle, M. Structure activity relationships of tetrahydrocan-
nabinol analogues on human cannabinoid receptors. Bioorg.
Med. Chem. Lett. 1996, 6, 189-194. (b) Showalter, V. M.;
Compton, D. R.; Martin, B. R.; Abood, E. Evaluation of binding
in a transfected cell line expressing a peripheral cannabinoid
receptor (CB2): Identification of cannabinoid receptor subtype
selective ligands. J . Pharmacol. Exp. Ther. 1996, 278, 989-999.
J M970126F